Dihexa vs Noopept

Dihexa is an angiotensin IV-derived peptide that potentiates HGF/c-Met signalling in rodent memory models. Noopept is a dipeptide-like compound registered in Russia and studied for cognitive function.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Dihexa

A small, blood–brain-barrier-permeable angiotensin IV analogue reported to act through the hepatocyte growth factor (HGF)/c-Met system.

BEST STUDIED FOR

Nootropic & neuro

Read the cited profile →

🧪

Noopept

A proline-containing dipeptide nootropic developed in Russia as a piracetam analogue, whose metabolite resembles an endogenous neuropeptide.

BEST STUDIED FOR

Nootropic & neuro

Read the cited profile →

SIDE BY SIDE

	Dihexa	Noopept
The key difference	Angiotensin IV analogue (HGF/c-Met)	Prolyl dipeptide (Russian nootropic)
Class	Nootropic & neuro	Nootropic & neuro
Mechanism	Dihexa was developed from angiotensin IV-related peptides with pro-cognitive effects.	Noopept is metabolised to cyclo-L-prolylglycine, an endogenous cyclic dipeptide.
Status	Preclinical only (rodent cognitive and neurodegeneration models, hair-cell protection, nerve repair). No human trials published.	Registered as a medicine in Russia; unapproved elsewhere. It has been found as an undeclared ingredient in US "cognitive" supplements.
Reported safety signals	No human safety data. Because HGF/c-Met is also an oncogenic pathway, long-term activation is a theoretical concern raised in the field.	Human data are limited to Russian clinical use; an FDA-related analysis found it among unapproved drugs in supplements, raising quality and dose concerns.
A key study	Reported that the pro-cognitive and synaptogenic effects of AngIV-derived peptides including dihexa depend on HGF/c-Met activation. (J Pharmacol Exp Ther 2014, PMID 25187433)	Identified noopept’s main brain metabolite as resembling the endogenous peptide cyclo-L-prolylglycine. (Eur J Drug Metab Pharmacokinet 1997, PMID 9358206)

WHEN TO RESEARCH WHICH

Dihexa is purely preclinical; noopept has some Russian clinical data. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Dihexa] The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system — J Pharmacol Exp Ther 2014. PMID 25187433
[Dihexa] AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway — Brain Sci 2021. PMID 34827486
[Dihexa] The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases — Prog Neurobiol 2015. PMID 25455861
[Noopept] The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine — Eur J Drug Metab Pharmacokinet 1997. PMID 9358206
[Noopept] Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model — Behav Pharmacol 1999. PMID 10780261
[Noopept] Five Unapproved Drugs Found in Cognitive Enhancement Supplements — Neurol Clin Pract 2021. PMID 34484905

FREQUENTLY ASKED

What is the difference between Dihexa and Noopept?

What is the regulatory status of Dihexa and Noopept?

Dihexa: Preclinical only (rodent cognitive and neurodegeneration models, hair-cell protection, nerve repair). No human trials published. Noopept: Registered as a medicine in Russia; unapproved elsewhere. It has been found as an undeclared ingredient in US "cognitive" supplements.

What safety signals have been reported?

Dihexa: No human safety data. Because HGF/c-Met is also an oncogenic pathway, long-term activation is a theoretical concern raised in the field. Noopept: Human data are limited to Russian clinical use; an FDA-related analysis found it among unapproved drugs in supplements, raising quality and dose concerns.

Which studies is this comparison based on?

For Dihexa: “The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system” (PMID 25187433); “AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway” (PMID 34827486); “The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases” (PMID 25455861). For Noopept: “The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine” (PMID 9358206); “Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model” (PMID 10780261); “Five Unapproved Drugs Found in Cognitive Enhancement Supplements” (PMID 34484905).